Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study

Table 2 Multivariate analysis^a for no remission according to each clinical index

	OR	95% CI	P-value
DAS28-ESR, no remission
Disease duration, years	1.02	1.00–1.05	0.10
Positive for rheumatoid factor	2.18	1.47–3.22	< 0.00
Previous use of bDMARDs	4.37	2.00–9.54	< 0.00
Presence of FAA	3.43	2.01–5.84	< 0.00
DAS28-CRP, no remission
Presence of lung disease	3.53	1.08–11.53	0.04
Positive for rheumatoid factor	1.64	1.18–2.29	< 0.00
Previous use of bDMARDs	4.25	2.47–7.31	< 0.00
Presence of FAA	3.59	2.43–5.33	< 0.00
SDAI, no remission
Previous use of bDMARDs	6.77	2.13–21.5	< 0.00
Presence of FAA	6.33	2.75–14.6	< 0.00
CDAI, no remission
Previous use of bDMARDs	5.94	1.44–24.49	< 0.00
Presence of FAA	7.59	2.37–24.33	< 0.00
RAPID, no remission
Use of MTX	2.6	0.94–7.23	0.07
Previous use of bDMARDs	8.22	2.59–26.11	< 0.00
Presence of FAA	5.57	2.69–11.52	< 0.00

^aFactors known to be associated with remission such as age, disease duration, the positivity of RF, positivity of anti-cyclic citrullinated peptide, the existence of lung disease, use of MTX, previous use of bDMARDs were included for multivariate logistic regression analysis

ISSN: 1471-2474